Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: NAC Clear all
Not listed Not applicable Interventional

N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring

NCT02865629
View directory record Official record
Conditions
Depression
Interventions
N-acetyl cysteine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol

NCT03104959
View directory record Official record
Conditions
Prevention of Hangover Using N-Acety Cysteine
Interventions
N-acetyl cysteine, placebo
Dietary Supplement · Other
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 22, 2026, 11:05 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

NCT00775476
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Role of Acetylcysteine in Creatinine Clearance

NCT00396396
View directory record Official record
Conditions
Creatinine Clearance
Interventions
Acetylcysteine
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2006 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational

Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen

NCT01936818
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational

Treatment of Acetaminophen Toxicity With N-acetylcysteine

NCT00725179
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

NCT00218491
View directory record Official record
Conditions
Cocaine Dependence
Interventions
N-Acetylcysteine, Matching Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

NCT00136825
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 22, 2026, 11:05 AM EDT
Recruiting No phase listed Observational

An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer

NCT07255729
View directory record Official record
Conditions
Colon Cancer
Interventions
Diagnostic Test: EXPOSE assay（Small RNA-seq of exosomal miRNAs）, Diagnostic Test: EXPOSE RT-qPCR panel
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 11:05 AM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

NCT00575419
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
N-acetylcysteine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02569957
View directory record Official record
Conditions
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Topotecan Hydrochloride, Acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 1 Interventional

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

NCT01090128
View directory record Official record
Conditions
Stages II-III Breast Cancer
Interventions
Nanoparticle Albumin Bound Paclitaxel, doxorubicin, cyclophosphamide
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 22, 2026, 11:05 AM EDT
Terminated Phase 3 Interventional Results available

NAC for Head Trauma-induced Anosmia

NCT03680911
View directory record Official record
Conditions
Anosmia, Head Trauma
Interventions
N Acetyl Cysteine, Placebo oral capsule
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetic Profile of N-Acetyl Cysteine

NCT06252519
View directory record Official record
Conditions
Pharmacokinetics
Interventions
NAC, Neuro-NAC, Neuro-NAC XS
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

NCT02259595
View directory record Official record
Conditions
Hearing Loss, Sensorineural Hearing Loss, Noise-Induced Hearing Loss
Interventions
HPN-07, NAC, Placebo
Drug
Lead sponsor
Otologic Pharmaceutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 4 Interventional Results available

Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis

NCT00028262
View directory record Official record
Conditions
Infantile Neronal Ceroid Lipofuscinosis
Interventions
Cystagon
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 3 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Phase 1 Interventional

Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer

NCT01878695
View directory record Official record
Conditions
Stage 0/1 Breast Cancer, Post Biopsy, Pre-surgery
Interventions
IV/oral n-acetylcysteine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jul 22, 2026, 11:05 AM EDT
Completed Early Phase 1 Interventional

Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence

NCT02994875
View directory record Official record
Conditions
Cocaine Dependence
Interventions
N-acetylcysteine, Placebo
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 22, 2026, 11:05 AM EDT
Completed No phase listed Observational

Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

NCT01465542
View directory record Official record
Conditions
Acetaminophen Toxicity
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jul 22, 2026, 11:05 AM EDT